Question 1

The financial reporting period for this document concludes on March 31, 2025.

Accepted Answer

According to "Supplementary Material for the Financial Results: Year Ended March 31, 2025": The financial reporting period for this document concludes on March 31, 2025.

Question 2

Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, and Kyushu Iyaku are collectively categorized as 'Towa Pharmaceutical, etc.' for domestic segment reporting.

Accepted Answer

According to "Supplementary Material for the Financial Results: Year Ended March 31, 2025": Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, and Kyushu Iyaku are collectively categorized as 'Towa Pharmaceutical, etc.' for domestic segment reporting.

Question 3

Sunsho Pharmaceutical, KAMATA, and Sun Freres Lab are identified as distinct entities within the company's organizational structure for financial reporting purposes.

Accepted Answer

According to "Supplementary Material for the Financial Results: Year Ended March 31, 2025": Sunsho Pharmaceutical, KAMATA, and Sun Freres Lab are identified as distinct entities within the company's organizational structure for financial reporting purposes.

Supplementary Material for the Financial Results: Year Ended March 31, 2025

Key insights

Summary

Citation

Related reports

FY26/3 Earnings Summary and Mid- to Long-Term Growth Strategies: Capcom

Fiscal Year Ended March 2026: Results Presentation

FY2025 Consolidated Financial Results

Consolidated Financial Results: Fiscal Year Ended March 31, 2026